Biotech Values

[dewophile]

I'm impressed at how quickly they were able to move forward the 31 valent program
GSK bought a program but they have yet to advance it and the 30+ still appears to be preclinical (unless they are in ultra stealth mode)
I'm not sure where PFE is w their program, and at what serotype number there starts to be serious diminishing returns (i.e. 31 might get you up to 85-90% coverage ). I honestly haven't followed the space closely, but PCVX has exceeded my expectations particularly on speed unless MRK/PFE/GSK are all tight lipped for competitive reasons